The life sciences community has gathered once again in San Francisco for the highly anticipated 2026 J.P. Morgan Healthcare Conference, a focal point for industry leaders to exchange insights and explore new opportunities. The event has already generated significant excitement, driven by a whirlwind of pre-conference transactions that have seen major pharmaceutical companies like Eli Lilly, GSK, and Roche injecting substantial sums into the biotech sector.
Fierce Biotech is on the ground, diligently monitoring the most impactful deals, emerging data, and noteworthy shifts within the industry. Attendees and stakeholders are encouraged to stay updated as the week progresses with real-time updates.
In a major development on Monday at 11:10 a.m. ET, Eli Lilly announced an expanded artificial intelligence collaboration with Nvidia, both companies boasting market capitalizations in the trillions. The two tech giants revealed plans to establish a co-innovation laboratory aimed at merging technology and biology to accelerate AI-driven drug development. A significant investment of $1 billion is earmarked for this initiative, with operations expected to commence in the Bay Area in the near future. The partnership builds upon an earlier agreement in which the organizations geared up to create what they claimed would be the pharmaceutical industry’s most powerful supercomputer.
Earlier on the same day, at 8 a.m. ET, Noubar Afeyan, Ph.D., co-founder of Moderna and CEO of Flagship Pioneering, issued a poignant letter addressing recent governmental actions that he argues jeopardize scientific integrity. He expressed concern over what he described as unfounded criticisms of mRNA technology and childhood vaccinations, warning that such attacks may undermine the foundations of scientific progress and, consequently, American health and innovation.
Afeyan underscored the scientific method’s fundamental principles, which include formulating hypotheses and validating them through rigorous experiments. He emphasized that policy decisions should ideally be informed by these scientifically derived findings. “We have plenty of money to deploy to this kind of activity,” he stated, “but the fact that it’s being withheld or directed in other ways—not through a scientific process but rather through a political process—is the thing that I think we have to correct.”
He cited the resurgence of measles as a stark example of the far-reaching consequences of unscientific policymaking. “The resurgence of measles is not the result of, say, a random genetic mutation. It is the result of choices, policy decisions, to turn our backs on decades of science,” Afeyan concluded.
As the week unfolds, the life sciences sector is poised for significant discussions and developments, all under the spotlight of the J.P. Morgan Healthcare Conference.
